10-Q: VolitionRx Narrows Loss, Expands Vet Test Reach

VolitionRx Limited reported a reduced net loss for the first half of 2025, driven by lower operating expenses, while expanding its Nu.Q Vet Cancer Test to 16 countries and securing new financing.

Summary

• VolitionRx Limited reported a net loss of $11.8 million for the six months ended June 30, 2025, a 24% reduction from the $15.5 million net loss in the same period of 2024.
• Total revenues increased by 15% to $653,073 for the first half of 2025, primarily driven by a 78% growth in Nu.Q Discover services.
• Operating expenses decreased by 22% to $12.5 million, largely due to a 36% reduction in research and development expenses and a 36% decrease in sales and marketing expenses.
• The company's cash and cash equivalents stood at $2.3 million as of June 30, 2025, with an accumulated deficit of $241.3 million.
• Net cash used in operating activities for the six months ended June 30, 2025, was $10.6 million, a decrease from $15.1 million in the prior year.
• Significant financing activities provided $9.3 million in cash, including proceeds from a $7.5 million senior secured convertible note and registered direct offerings.
• The Nu.Q Vet Cancer Test is now commercially available in sixteen countries, following launches in the UK, Ireland, and Japan.

Sentiment

Score: 4

Explanation: The company shows progress in reducing net loss and operating expenses, and has expanded its veterinary product's commercial reach. However, the persistent 'going concern' warning, substantial accumulated deficit, and identified material weakness in internal controls indicate significant financial instability and high operational risk, outweighing the positive developments.

Positives

• Net loss significantly decreased by 24% to $11.8 million for the six months ended June 30, 2025, compared to $15.5 million in the prior year.
• Total revenues increased by 15% to $653,073, with services revenue growing by 78% to $277,254.
• Operating expenses decreased by 22% to $12.5 million, driven by a 36% reduction in research and development expenses and a 36% decrease in sales and marketing expenses.
• The Nu.Q Vet Cancer Test has expanded its commercial availability to sixteen countries, indicating growing market penetration.
• Secured $5.8 million in net cash proceeds from a new senior secured convertible note and $2.3 million from a registered direct offering in March 2025, bolstering liquidity.
• Received $13.0 million in milestone payments from Heska (now Antech Company) related to the Nu.Q Vet Cancer Test license agreement.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $241.3 million as of June 30, 2025.
• Cash and cash equivalents are low at $2.3 million as of June 30, 2025, and the company has experienced negative cash flows from operations since inception.
• Auditors and management have identified substantial doubt about the company's ability to continue as a going concern beyond one year.
• General and administrative expenses increased by 14% to $5.2 million, primarily due to higher stock-based compensation and legal/professional fees.
• A material weakness in internal controls over financial reporting was identified due to insufficient written documentation of policies and procedures.
• The new convertible note introduces a derivative liability of $623,790 and significant debt obligations, with potential default penalties of 120% of outstanding principal.

Risks

• Inability to generate significant revenues or achieve profitability, leading to continued operating losses and negative cash flows.
• The need to raise additional capital in the future, with no assurance of success or favorable terms, potentially leading to dilution or restrictive debt covenants.
• Difficulties in managing growth if product development and sales/marketing capabilities expand rapidly.
• Dependence on third-party distributors for product commercialization.
• Limited experience with sales and marketing, which could hinder market penetration.
• The possibility that the company may not be able to continue to operate as a going concern.
• Challenges in successfully developing, manufacturing, marketing, and selling future products.
• Delays or inability to obtain necessary regulatory clearances or approvals for future products.
• Lack of market acceptance for future products.
• The highly competitive and rapidly changing nature of the diagnostics market.
• Challenges in protecting patents, intellectual property, and trade secrets.
• Reliance on third parties for manufacturing and supply of intended products, and their dependence on third-party suppliers.
• Material weaknesses in internal control over financial reporting, which could lead to undetected material misstatements.
• Pressures related to macroeconomic and geopolitical conditions impacting business operations.

Future Outlook

VolitionRx aims to transition from a research and development stage to a commercialization stage, focusing on monetizing its intellectual property through licensing and distribution contracts with global and regional partners. The company expects to continue developing its clinical-stage diagnostic tests and commercialization activities, which will likely result in further losses. Future operations are dependent on securing additional capital through licensing, debt or equity transactions, and grant funds, while maintaining tight cost controls. The company believes its low-cost, accessible tests could be used worldwide for cancer and NETosis-associated diseases. Management's plans do not alleviate substantial doubt about the company's ability to continue as a going concern beyond one year.

Management Comments

• "Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That's the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests."
• "We aim to partner with established diagnostic companies and/or liquid biopsy companies to market, sell, and process our tests, leveraging their networks and expertise."
• "We believe, given the global prevalence of cancer and diseases associated with NETosis, and the low-cost, accessible and routine nature of our tests, they could potentially be used throughout the world."
• "We aim to remain an IP powerhouse in the epigenetic space and expect to monetize our IP and technologies through licensing and distribution contracts with companies that have established distribution networks and expertise on a worldwide or regional basis, in both human and animal care across platforms (centralized labs and point-of-care / in-house diagnostics)."
• "Management plans to address the above as needed by, (a) granting licenses and/or distribution rights to third parties in exchange for specified up-front and/or back-end payments, (b) obtaining additional financing through debt or equity transactions, (c) securing additional grant funds, and (d) developing and commercializing its products in an efficient manner."
• "Management continues to exercise tight cost controls to conserve cash."
• "The Company concluded that these plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued."

Industry Context

VolitionRx operates within the highly competitive and rapidly evolving diagnostics market, specifically focusing on epigenetics and nucleosome-based biomarkers for early disease detection and monitoring in both human and animal health. The company's strategy of partnering with established diagnostic companies like Heska (Antech) and IDEXX aligns with a trend in the diagnostics industry where smaller, innovative biotech firms leverage the broader distribution networks and market access of larger players. The focus on 'liquid biopsy' and 'early detection' positions VolitionRx in a high-growth segment of the diagnostics market, driven by increasing demand for less invasive and more accessible screening methods. The expansion of the Nu.Q Vet Cancer Test into more countries reflects a growing global market for advanced veterinary diagnostics.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. However, the company's strategy of partnering with established diagnostic companies like Heska (now Antech Company) and IDEXX suggests an approach common among early-stage diagnostic developers seeking to leverage existing market infrastructure.
• The expansion of the Nu.Q Vet Cancer Test into sixteen countries, including key markets like Japan, indicates a level of commercial traction that, while not quantified against specific industry benchmarks, suggests successful initial market entry and adoption within the veterinary diagnostics sector.
• The continued reliance on external financing and the 'going concern' warning indicate that the company's financial health and operational maturity are below the standards of established, profitable diagnostic companies, aligning more with early-stage biotech firms that are still heavily investing in R&D and market development.

Corporate Governance

Legal Proceedings

• The company is not aware of any material, existing or pending legal proceedings against it, nor is it involved as a plaintiff in any material proceeding or pending litigation.

Related Party Transactions

• Common stock was issued to certain directors and executive officers in the March 2025 registered direct offering (2,363,636 shares at $0.55 per share).
• Common stock was issued to certain directors and executive officers in the August 2025 registered direct offering (156,250 shares at $0.64 per share).
• Directors and certain employees have elected to exchange a portion of their fees earned or paid in cash or salary, respectively, for Restricted Stock Units (RSUs) in the company.
• The company has agreements with related parties for the purchase of consultancy services, which are accrued under management and directors fees payable.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing equity offerings and potential future conversions of the convertible note. The 'going concern' warning indicates substantial risk to investment value. However, reduced losses and commercial expansion offer some potential for future value.
• **Employees:** Benefit from stock-based compensation and potential cash bonuses tied to corporate goals, but face uncertainty due to the company's going concern status and cost-saving initiatives.
• **Customers (Veterinary & Research):** Benefit from the expanded availability of Nu.Q Vet Cancer Test and Nu.Q Discover services, offering new diagnostic tools.
• **Creditors (Lind Global Asset Management XII LLC):** Hold a senior secured convertible promissory note, providing a priority claim on assets and significant control through covenants and default provisions, but are exposed to the company's ability to generate future cash flows or raise capital.
• **Suppliers/Partners:** Continued collaboration with research partners (e.g., University of Taiwan, MD Anderson) and commercial partners (e.g., Heska, IDEXX, Fujifilm Vet Systems) is crucial for the company's strategic execution and product development.

Next Steps

• Continue to develop clinical-stage diagnostic tests and commercialization activities.
• Grant licenses and/or distribution rights to third parties for upfront and/or back-end payments.
• Obtain additional financing through debt or equity transactions.
• Secure additional grant funds.
• Develop and commercialize products in an efficient manner.
• Implement remediation plans to address material weaknesses in internal control over financial reporting, including centralizing accounting, engaging internal control consultants, and preparing written documentation of policies and procedures.
• Pay cash bonuses to salaried employees in January 2026 upon achievement of corporate goals related to licensing, revenue, cost reduction, and non-dilutive funding.
• RSUs granted in March 2025 are expected to vest in approximately one-third increments on March 17, 2026, March 17, 2027, and March 17, 2028, subject to continued service and corporate goal achievement.
• RSUs issued in July 2025 to executive officers are subject to vesting upon achieving a closing stock price target above $2.50 for 30 consecutive trading days prior to July 24, 2028, but not earlier than July 24, 2026, and time-based vesting six months after target achievement.

Key Dates

Recommendation

VolitionRx is in a critical transition phase, showing positive signs in revenue growth from services and significant reductions in operating losses, particularly in R&D. The expansion of the Nu.Q Vet Cancer Test into new markets and strategic partnerships are encouraging. However, the persistent 'going concern' warning, substantial accumulated deficit, and reliance on continuous external financing present considerable financial risk. The identified material weakness in internal controls adds an operational concern. For a seasoned investor, the current situation suggests a highly speculative investment. A 'hold' recommendation is appropriate for existing investors who are willing to tolerate high risk and await further clarity on the company's path to profitability and resolution of its going concern status, given the active efforts to commercialize products and secure funding. For new investors, the risks currently outweigh clear upside potential, suggesting caution.

Keywords

Epigenetics, Cancer Diagnostics, Sepsis Diagnostics, Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Liquid Biopsy, Biomarkers, Veterinary Diagnostics, Human Diagnostics, SEC Filing, 10-Q, Biotechnology, Healthcare